15675610|t|SGS-742 Novartis.
15675610|a|SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.
15675610	0	7	SGS-742	Chemical	MESH:C079148
15675610	18	25	SGS-742	Chemical	MESH:C079148
15675610	144	164	cognitive impairment	Disease	MESH:D003072
15675610	169	188	Alzheimer's disease	Disease	MESH:D000544
15675610	190	192	AD	Disease	MESH:D000544
15675610	255	262	SGS-742	Chemical	MESH:C079148
15675610	283	285	AD	Disease	MESH:D000544
15675610	286	294	patients	Species	9606
15675610	Negative_Correlation	MESH:C079148	MESH:D000544
15675610	Negative_Correlation	MESH:C079148	MESH:D003072

